Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Listen to expert insights on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Keith S. Kaye, MD, MPH
Program Director
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Jason Pogue Headshot
Jason M. Pogue, PharmD
Released: March 15, 2022

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:

  • Epidemiology and burden of nosocomial bacterial pneumonia
  • Patient-specific risk factors for MDR pathogens
  • Improving outcomes with the use of antibiograms
  • Recommended empiric therapy for clinically suspected VABP
  • Antimicrobial resistance in HABP/VABP
  • Algorithms for gram-negative organism antibiotic-susceptibility testing
  • Using rapid diagnostic tests for HABP/VABP
  • New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
    • ASPECT-NP: ceftolozane/tazobactam vs meropenem
    • REPROVE: ceftazidime/avibactam vs meropenem
    • RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
    • RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
    • APEKS-NP: cefiderocol vs meropenem
    • CREDIBLE-CR: cefiderocol vs best available therapy


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Program Director

Keith S. Kaye, MD, MPH

Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH, has disclosed that he has received consulting fees from Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, Contrafect, Cubist, Entasis, Integrated Operations, Melinta, Merck, Nabriva, NS Nanotech, Pratek, QPex, Shionogi, SPERO, Utility Therapeutics, VenatoRX, and Xellia.


Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Lilian Abbo, MD, FIDSA, has disclosed that she has received consulting fees from Ferring.
Jason M. Pogue, PharmD

Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Jason M. Pogue, PharmD, has disclosed that he has received consulting fees from Entasis, GlaxoSmithKline, Merck, QPex, Shionogi, Spero, and Utility.

Program Medium

This program has been made available online.

Related Content

Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)

person default Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 18, 2022

Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)

Clinical Care Options (CCO) presents expert faculty discussing RSV in certain adult populations and the development of RSV vaccines

John J. Russell, MD, FAAFP
Program Director
Laura Hurley, MD, MPH Pamela Rockwell, DO, FAAFP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Released: October 28, 2022 Expired: October 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings